{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:51:22Z","timestamp":1778878282947,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:00:00Z","timestamp":1604016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"China National Science and Technology major projects 12th 5-year plan","award":["2012ZX10005004"],"award-info":[{"award-number":["2012ZX10005004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12072-020-10097-z","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T17:04:01Z","timestamp":1604077441000},"page":"985-996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial"],"prefix":"10.1007","volume":"14","author":[{"given":"Xiaoke","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daqiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingjiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dewen","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qikai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianchun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianzhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danan","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-5835","authenticated-orcid":false,"given":"Yong\u2019an","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,30]]},"reference":[{"issue":"10003","key":"10097_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"S Aparna","year":"2015","unstructured":"Aparna S, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet (London, England). 2015;386(10003):1546\u201355.","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10097_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212\u20139.","journal-title":"Vaccine"},{"issue":"1","key":"10097_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1086\/599332","volume":"200","author":"L Xiaofeng","year":"2009","unstructured":"Xiaofeng L, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992\u20132005 in China. J Infect Dis. 2009;200(1):39\u201347.","journal-title":"J Infect Dis"},{"issue":"47","key":"10097_CR4","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","volume":"27","author":"X Liang","year":"2009","unstructured":"Liang X, et al. Epidemiological serosurvey of hepatitis B in China\u2013declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27(47):6550\u20137.","journal-title":"Vaccine"},{"issue":"1","key":"10097_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"KS Sarin","year":"2016","unstructured":"Sarin KS, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1\u201398.","journal-title":"Hepatol Int"},{"issue":"1","key":"10097_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","volume":"46","author":"L Shi-Ming","year":"2007","unstructured":"Shi-Ming L, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46(1):45\u201352.","journal-title":"J Hepatol"},{"issue":"2","key":"10097_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/hep.28594","volume":"64","author":"D Liu","year":"2016","unstructured":"Liu D, et al. Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity. Hepatology. 2016;64(2):390\u2013404.","journal-title":"Hepatology"},{"issue":"15","key":"10097_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"Y-F Liaw","year":"2009","unstructured":"Liaw Y-F, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2009;351(15):1521\u201331.","journal-title":"N Engl J Med"},{"issue":"16","key":"10097_CR9","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3748\/wjg.v16.i16.2028","volume":"16","author":"WS Xu","year":"2010","unstructured":"Xu WS, et al. Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro. World J Gastroenterol. 2010;16(16):2028\u201337.","journal-title":"World J Gastroenterol"},{"key":"10097_CR10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.taap.2017.03.016","volume":"323","author":"H Huang","year":"2017","unstructured":"Huang H, et al. Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs. Toxicol Appl Pharmacol. 2017;323:36\u201343.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"10097_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.eujim.2014.01.005","volume":"6","author":"K Cao","year":"2014","unstructured":"Cao K, et al. Efficacy of Zhengtian Pill for migraine prophylaxis: A randomized, multicenter, double-blind, placebo-controlled, parallel-group study. Eur J Integr Med. 2014;6(3):259\u201367.","journal-title":"Eur J Integr Med"},{"issue":"1","key":"10097_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jep.2013.10.033","volume":"151","author":"K Jeung-Bae","year":"2014","unstructured":"Jeung-Bae K, et al. A traditional herbal formula, Hyangsa-Pyeongwi san (HPS), improves quality of life (QoL) of the patient with functional dyspepsia (FD): randomized double-blinded controlled trial. J Ethnopharmacol. 2014;151(1):279\u201386.","journal-title":"J Ethnopharmacol"},{"key":"10097_CR13","unstructured":"Yong-An Y, et al Effect of Shuanghu Qinggan Granule () and Yigan Yiqi Jieyu Granule () plus lamivudine on chronic hepatitis B patients: a randomized double-blind placebo-controlled trial. Chin J Integr Med, 2016."},{"issue":"9","key":"10097_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s11655-018-3011-5","volume":"24","author":"Y Yong-An","year":"2018","unstructured":"Yong-An Y, et al. Chinese herbal medicine combined with entecavir for HBeAg positive chronic hepatitis B: study protocol for a multi-center, double-blind randomized-controlled trial. Chin J Integr Med. 2018;24(9):653\u201360.","journal-title":"Chin J Integr Med"},{"key":"10097_CR15","first-page":"13","volume":"3","author":"Disease, C.S.o.H.a.C.S.o.I","year":"2011","unstructured":"Disease, C.S.o.H.a.C.S.o.I. Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Chin J Hepatol (Chin). 2011;3:13\u201324.","journal-title":"Chin J Hepatol (Chin)."},{"issue":"7","key":"10097_CR16","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/ajg.2011.45","volume":"106","author":"MF Yuen","year":"2011","unstructured":"Yuen MF, et al. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011;106(7):1264\u201371.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10097_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/hep.24406","volume":"54","author":"R Zoutendijk","year":"2011","unstructured":"Zoutendijk R, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology. 2011;54(2):443\u201351.","journal-title":"Hepatology"},{"issue":"6","key":"10097_CR18","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jhep.2009.12.036","volume":"52","author":"O Yokosuka","year":"2010","unstructured":"Yokosuka O, et al. Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol. 2010;52(6):791\u20139.","journal-title":"J Hepatol"},{"key":"10097_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2893.2010.01271.x","volume":"17","author":"GB Yao","year":"2010","unstructured":"Yao GB, et al. Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients. J Viral Hepatitis. 2010;17:51\u20138.","journal-title":"J Viral Hepatitis"},{"issue":"4","key":"10097_CR20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","volume":"65","author":"J Wang","year":"2016","unstructured":"Wang J, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65(4):700\u201310.","journal-title":"J Hepatol"},{"issue":"2","key":"10097_CR21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address, e.e.e. and L. European Association for the Study of the, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370\u201398.","journal-title":"J Hepatol."},{"issue":"2","key":"10097_CR22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3851\/IMP3280","volume":"24","author":"H Liao","year":"2019","unstructured":"Liao H, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside\/nucleotide analogue therapy. Antivir Ther. 2019;24(2):105\u201315.","journal-title":"Antivir Ther"},{"issue":"1","key":"10097_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology (Baltimore, MD). 2016;63(1):261.","journal-title":"Hepatology (Baltimore, MD)"},{"issue":"4","key":"10097_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.14218\/JCTH.2016.00019","volume":"5","author":"H Jinlin","year":"2017","unstructured":"Jinlin H, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 Update). J Clin Transl Hepatol. 2017;5(4):297\u2013318.","journal-title":"J Clin Transl Hepatol"},{"issue":"4","key":"10097_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","volume":"67","author":"AS Lok","year":"2017","unstructured":"Lok AS, et al. Hepatitis B cure: from discovery to regulatory approval. J Hepatol. 2017;67(4):847\u201361.","journal-title":"J Hepatol"},{"issue":"5","key":"10097_CR26","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1053\/j.gastro.2007.08.025","volume":"133","author":"GR Gish","year":"2007","unstructured":"Gish GR, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133(5):1437\u201344.","journal-title":"Gastroenterology"},{"issue":"1","key":"10097_CR27","first-page":"31","volume":"53","author":"CM Kemal","year":"2014","unstructured":"Kemal CM, et al. Four-year study of entecavir efficacy and safety in nucleos(t)ide-na\u00efve HBeAg positive chronic hepatitis B patients. Acta Clinica Croatica. 2014;53(1):31\u20136.","journal-title":"Acta Clinica Croatica"},{"issue":"1","key":"10097_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cgh.2013.04.036","volume":"12","author":"Y Suna","year":"2014","unstructured":"Suna Y, Nizar T, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol. 2014;12(1):16\u201326.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"10097_CR29","doi-asserted-by":"publisher","first-page":"590","DOI":"10.5009\/gnl16215","volume":"11","author":"S Tung-Hung","year":"2017","unstructured":"Tung-Hung S, Chun-Jen L. Combination therapy for chronic hepatitis B: current updates and perspectives. Gut Liver. 2017;11(5):590\u2013603.","journal-title":"Gut Liver"},{"issue":"4","key":"10097_CR30","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jhep.2014.05.044","volume":"61","author":"Q Ning","year":"2014","unstructured":"Ning Q, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol. 2014;61(4):777\u201384.","journal-title":"J Hepatol"},{"issue":"4","key":"10097_CR31","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s40121-017-0173-y","volume":"6","author":"JE Arends","year":"2017","unstructured":"Arends JE, et al. New viral and immunological targets for hepatitis B treatment and cure: a review. Infect Dis Therapy. 2017;6(4):461\u201376.","journal-title":"Infect Dis Therapy."},{"issue":"4","key":"10097_CR32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0168-8278(03)00292-7","volume":"39","author":"B Carolina","year":"2003","unstructured":"Carolina B, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol. 2003;39(4):595\u2013605.","journal-title":"J Hepatol"},{"issue":"4","key":"10097_CR33","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","volume":"143","author":"B Carolina","year":"2012","unstructured":"Carolina B, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012;143(4):963-973.e9.","journal-title":"Gastroenterology"},{"issue":"7","key":"10097_CR34","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1172\/JCI118592","volume":"97","author":"B Rehermann","year":"1996","unstructured":"Rehermann B, et al. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest. 1996;97(7):1655\u201365.","journal-title":"J Clin Invest."},{"issue":"2","key":"10097_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/cpdd.317","volume":"6","author":"NJ Shire","year":"2017","unstructured":"Shire NJ. Cure strategies for hepatitis B virus: the promise of immunotherapy. Clin Pharmacol Drug Dev. 2017;6(2):186\u201394.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"10097_CR36","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.ijbiomac.2017.10.171","volume":"108","author":"Y Hua","year":"2018","unstructured":"Hua Y, et al. Hepatoprotective and inhibiting HBV effects of polysaccharides from roots of Sophora flavescens. Int J Biol Macromol. 2018;108:744\u201352.","journal-title":"Int J Biol Macromol"},{"key":"10097_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/767290","volume":"2013","author":"L Min","year":"2013","unstructured":"Min L, et al. Modeling and simulating dynamics of complete- and poor-response chronic hepatitis b chinese patients for adefovir and traditional chinese medicine plus adefovir therapy. Evid-Based Complement Altern Med. 2013;2013:1\u201312.","journal-title":"Evid-Based Complement Altern Med"},{"issue":"5","key":"10097_CR38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s11655-020-3250-0","volume":"26","author":"XK Li","year":"2020","unstructured":"Li XK, et al. Adefovir dipivoxil plus chinese medicine in HBeAg-positive chronic hepatitis B patients: a randomized controlled 48-week trial. Chin J Integr Med. 2020;26(5):330\u20138.","journal-title":"Chin J Integr Med"},{"key":"10097_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jpba.2017.02.015","volume":"138","author":"J Xing","year":"2017","unstructured":"Xing J, et al. Integrative hepatoprotective efficacy comparison of raw and vinegar-baked Radix Bupleuri using nuclear magnetic resonance-based metabolomics. J Pharm Biomed Anal. 2017;138:215\u201322.","journal-title":"J Pharm Biomed Anal"},{"key":"10097_CR40","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.fct.2017.12.020","volume":"111","author":"M Kondeva-Burdina","year":"2018","unstructured":"Kondeva-Burdina M, et al. In vitro\/in vivo antioxidant and hepatoprotective potential of defatted extract and flavonoids isolated from Astragalus spruneri Boiss. (Fabaceae). Food Chem Toxicol. 2018;111:631\u201340.","journal-title":"Food Chem Toxicol"},{"issue":"3","key":"10097_CR41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1046\/j.1440-1746.2003.02976.x","volume":"18","author":"L Yun-Fan","year":"2003","unstructured":"Yun-Fan L. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol. 2003;18(3):246\u201352.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"10097_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1872-034X.2008.00411.x","volume":"39","author":"M Ri-Cheng","year":"2009","unstructured":"Ri-Cheng M, et al. Spontaneous HBeAg seroconversion and loss of hepatitis B virus DNA after acute flare due to development of drug resistant mutants during entecavir monotherapy. Hepatol Res. 2009;39(1):14\u201320.","journal-title":"Hepatol Res"},{"issue":"4","key":"10097_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/jvh.12833","volume":"25","author":"WJ Jeng","year":"2018","unstructured":"Jeng WJ, Chen YC, Liaw YF. Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy. J Viral Hepat. 2018;25(4):421\u20138.","journal-title":"J Viral Hepat"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10097-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-020-10097-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10097-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T19:29:23Z","timestamp":1610566163000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-020-10097-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,30]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10097"],"URL":"https:\/\/doi.org\/10.1007\/s12072-020-10097-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,30]]},"assertion":[{"value":"14 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study (involving human participants) were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}